Christian Itin

Dr Itin currently serves as the Chief Executive Officer and Chairman of the Board of Autolus Therapeutics plc, a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours. Dr Itin is a leader in the immuno-oncology field.

Previously he served as President and CEO at Micromet Inc., a former NASDAQ-listed biopharmaceutical company, which was acquired in 2012 by Amgen. At Micromet, Dr Itin and his team pioneered the field of T-cell engaging antibodies, or BiTEs. The lead programme, blinatumomab, obtained approval by the FDA as breakthrough therapy for the treatment of patients with acute lymphoblastic leukemia. Dr Itin spent 13 years with Micromet in a number of senior management roles, becoming CEO in 2004.

He continues to serve as Chairman of Autolus and Kuros Biosciences AG. From November 2012 to January 2016 he served as Chief Executive Officer and Chairman of Cytos Biotechnology Ltd.